ONCOLYTICS BIOTECH INC 8-K

What Happened

• On March 2, 2026, Oncolytics Biotech, Inc. announced (via press release and Form 8‑K, Item 8.01) the launch of REO 033, a randomized clinical study in second‑line RAS‑mutant, microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) patients. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: March 2, 2026 (Form 8‑K, Item 8.01).
• Study name: REO 033 — randomized study in second‑line RAS‑mutant, MSS mCRC.
• Disclosure: Announcement made via press release (Exhibit 99.1); the 8‑K does not disclose trial size, endpoints, timelines, or financial results.
• Signature: Report filed and signed on behalf of the company by CFO Kirk Look.

Why It Matters

• The filing is a clinical development update: launching a randomized study is a material operational milestone for a biotech company. Investors should note the company has advanced this program to a randomized study stage; additional filings or press releases with trial design, enrollment progress, interim data, or timing will be material to evaluate impact. The 8‑K did not report financial results or management changes.